vs study ≥27 ≤18.6 2.70 (0.94-7.60) ng/ml area, vitamin use 54/ Incidence, rectal 102 controls cancer, women vs ≥27 ≤18.6 0.33 (0.08-1.30) ng/ml vs ≥32.1 ≤22.8 0.07 (0.01-0.99) ng/ml 44/ Incidence, rectal 87 controls cancer, men vs 4.60 ≥32.1 ≤22.8 ng/ml Table 228 Serum vitamin D and colorectal cancer risk. Main characteristics of studies excluded from the CUP SLR dose-response analysis Cases/ Author, Year, Study name, Study size Case Exposure RR (95%CI) Adjustment Reasons for WCRF Code, Outcome Comparison characteristics Follow-up ascertainment assessment Ptrend factors exclusion Country (years) Age, sex, NHS-HPFS, alcohol, aspirin Prospective Self-report use, BMI, Jung, 2014 Cohort, verified by The exposure 1 059/ Incidence, calcium, COL41053 Age: 30-75 medical record Q 5 vs Q 1 0.55 (0.43-0.71) was predicted 140 418 colorectal cancer endoscopy, USA M/W, and pathology vitamin D score family history of Health report colorectal professionals cancer, height,
study area, vitamin use 54/ 102 controls Incidence, rectal cancer, women ≥27 vs ≤18.6 ng/ml 2.70 (0.94-7.60) ≥27 vs ≤18.6 ng/ml 0.33 (0.08-1.30) 44/ 87 controls Incidence, rectal cancer, men ≥32.1 vs ≤22.8 ng/ml 0.07 (0.01-0.99) ≥32.1 vs ≤22.8 ng/ml 4.60 Table 228 Serum vitamin D and colorectal cancer risk. Main characteristics of studies excluded from the CUP SLR dose-response Author, Year, WCRF Code, Country Study name, characteristics Cases/ Study size Follow-up (years) Case ascertainment Exposure assessment Outcome Comparison RR (95%CI) Ptrend Adjustment factors Reasons for exclusion Jung, 2014 COL41053 USA NHS-HPFS, Prospective Cohort, Age: 30-75 M/W, Health professionals 1 059/ 140 418 Self-report verified by medical record and pathology report Incidence, colorectal cancer Q 5 vs Q 1 0.55 (0.43-0.71) Age, sex, alcohol, aspirin use, BMI, calcium, endoscopy, family history of colorectal cancer, height, The exposure was predicted vitamin D score analysis
CUP_colorectal_SLR_2016_RO.docx